Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ROBERT C BAST JR and KAREN H LU.
ROBERT C BAST JR
Connection Strength
1.994
KAREN H LU
  1. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 01; 119(19):3454-61.
    View in: PubMed
    Score: 0.457
  2. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004 May 15; 10(10):3291-300.
    View in: PubMed
    Score: 0.240
  3. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2504-2512.
    View in: PubMed
    Score: 0.187
  4. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012 Apr; 206(4):351.e1-8.
    View in: PubMed
    Score: 0.102
  5. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer. 2012 Jan 01; 118(1):91-100.
    View in: PubMed
    Score: 0.098
  6. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol. 2011 Sep; 122(3):548-53.
    View in: PubMed
    Score: 0.098
  7. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008 Aug; 110(2):196-201.
    View in: PubMed
    Score: 0.079
  8. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008 Apr 01; 112(7):1489-502.
    View in: PubMed
    Score: 0.078
  9. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol. 2007 Sep; 106(3):490-7.
    View in: PubMed
    Score: 0.074
  10. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007; 174:91-100.
    View in: PubMed
    Score: 0.072
  11. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005 Sep 01; 11(17):6116-26.
    View in: PubMed
    Score: 0.066
  12. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005 Nov; 99(2):267-77.
    View in: PubMed
    Score: 0.065
  13. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res. 2004 Oct 01; 10(19):6559-66.
    View in: PubMed
    Score: 0.062
  14. Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002; 107:61-97.
    View in: PubMed
    Score: 0.051
  15. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev Res (Phila). 2015 Jan; 8(1):37-48.
    View in: PubMed
    Score: 0.031
  16. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6.
    View in: PubMed
    Score: 0.029
  17. Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care. Cancer Prev Res (Phila). 2012 May; 5(5):706-16.
    View in: PubMed
    Score: 0.026
  18. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012 Apr; 206(4):349.e1-7.
    View in: PubMed
    Score: 0.025
  19. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011 Mar; 4(3):365-74.
    View in: PubMed
    Score: 0.024
  20. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011 Mar; 4(3):375-83.
    View in: PubMed
    Score: 0.024
  21. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010 May 01; 28(13):2159-66.
    View in: PubMed
    Score: 0.023
  22. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer. 2009 Sep 01; 115(17):3897-908.
    View in: PubMed
    Score: 0.022
  23. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006 Mar 01; 66(5):2740-8.
    View in: PubMed
    Score: 0.017
  24. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005 Mar 15; 11(6):2149-55.
    View in: PubMed
    Score: 0.016
  25. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3534-45.
    View in: PubMed
    Score: 0.014
  26. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003 Jul; 90(1):44-50.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.